Hair shedding on GLP-1 therapy is real and well-documented. In the SURMOUNT-1 trial for Zepbound, approximately 5.7% of patients on the highest dose (15 mg) reported alopecia, compared to ~1% on placebo. The Wegovy STEP trials showed similar rates. This guide is what's actually known.
The mechanism is telogen effluvium
The hair shedding is not specific to GLP-1 receptor agonism. It's telogen effluvium — a generalized stress response that shifts hair follicles from active growth (anagen) into resting (telogen), with mass shedding 2–4 months later. Any rapid weight loss of similar magnitude produces this.
Who is at higher risk
- Patients losing weight faster than ~1% of body weight per week
- Patients with low protein intake
- Patients with iron deficiency or ferritin below 50 ng/mL
- Patients with vitamin D deficiency (below 30 ng/mL)
- Patients with thyroid disorders (T3, T4, TSH should be checked)
- Women in the postpartum window or perimenopausal
What actually helps
- Protein adequacy at 1.6 g/kg body weight — the single highest-leverage intervention
- Iron and ferritin testing — supplement if ferritin under 50 ng/mL (and ideally over 70 for women with hair concerns)
- Vitamin D testing — supplement to 50–60 ng/mL if low
- Slow titration — the SURMOUNT data on rapid escalators vs slow escalators suggests slower titration reduces shedding incidence
- Thyroid panel — rule out subclinical hypothyroidism, which independently contributes to shedding
When hair comes back
Telogen effluvium is reversible. Once the trigger (rapid weight loss) stabilizes, follicles re-enter growth phase. Visible regrowth begins within 4–6 months. Full recovery typically takes 9–18 months. The hair that grows back is your normal hair — not thinner or different in pattern, unlike androgenetic alopecia.
Does this mean you should stop the drug?
For most patients, no. Telogen effluvium from weight loss is self-limiting and reverses. Slowing titration and addressing micronutrient adequacy resolves most cases. If hair loss continues for more than 12 months despite intervention, evaluation for an unrelated cause (androgenetic, autoimmune, scarring alopecia) is appropriate.
NexLife scored highest on our rubric (94/100) for rigorous safety oversight. Flat-rate pricing across full titration, labs included, MD/DO oversight, both 503A and 503B pharmacy partners.
This article was authored by Eduard Cristea and clinically reviewed by Dr. A. Goher, MD. Health Technology Researcher & Publisher. See our methodology and affiliate disclosure.